经桡动脉入路置入FDA新批准动脉瘤器械的技术报告
本文报告首10例未破裂脑动脉瘤经桡动脉脑血管造影并置入WEB、PulseRider或Surpass装置的经验,所有患者均完成桡动脉置管、无需转股动脉,9例一次置入成功,1例WEB装置疝入载瘤动脉改行弹簧圈栓塞,术后无并发症。
要点
- 经桡动脉入路可完成WEB、PulseRider、Surpass三种新器械的置入
- 10例中9例一次置入成功,1例WEB疝入载瘤动脉改弹簧圈栓塞
- 术后无并发症,次日出院时改良Rankin量表评分与术前相同
核心结论
- 经桡动脉置管置入WEB、Surpass、PulseRider安全可行,无置管或释放限制,1例改弹簧圈栓塞可经同一血管通路完成,术后无血管并发症且腕部不适轻微。
研究设计与样本
- 单中心技术报告,回顾首批10例经桡动脉脑血管造影治疗的未破裂脑动脉瘤患者;其中7例用WEB、1例用PulseRider、2例用Surpass行栓塞。
主要发现
- 治疗的动脉瘤包括颈内动脉分叉、大脑中动脉、前交通动脉、基底动脉尖及后交通动脉。
- 10例均完成桡动脉置管,无一例转为股动脉入路。
- 10例中9例一次尝试即准确释放装置。
- 1例WEB装置疝入载瘤动脉致置入失败,改行弹簧圈栓塞。
- 术后无并发症,次日出院时改良Rankin量表评分与术前相同。
临床怎么用
- 对适合血管内治疗的未破裂脑动脉瘤,可考虑经桡动脉通路置入WEB、Surpass、PulseRider,失败时可经同一通路改弹簧圈栓塞。
局限性
- 样本仅10例,为单中心技术报告,无对照,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the recent increase of transradial access among neurointerventionalists, there is still a paucity of evidence in the neurosurgical literature. There are 3 newly Food and Drug Administration-approved devices-Woven EndoBridge (WEB), Surpass, and PulseRider-that significantly expand the options available for endovascular treatment of cerebral aneurysms. Our work reports the safety and feasibility of radial artery catheterization for the deployment of these new devices. METHODS: We performed a review of the first 10 patients with an unruptured cerebral aneurysm treated via a transradial cerebral angiogram. Seven patients underwent embolization with the WEB device, 1 patient underwent embolization with the PulseRider, and 2 patients underwent embolization with the Surpass device. We describe in detail our workflow and the devices used for transradial access. RESULTS: The aneurysms treated include internal carotid artery bifurcation, middle cerebral artery, anterior communicating artery, basilar tip, and posterior communicating artery. All patients underwent radial artery catheterization, and none of them had to be converted to femoral artery access. Of the 10 patients, 9 required a single attempt for accurate device deployment. One patient had unsuccessful placement of the WEB device and required coiling of the aneurysm because of device herniation into the parent vessel. None of the patients had any postoperative complications and were discharged the following day with the same modified Rankin scale score as preoperatively. CONCLUSIONS: Our experience with 10 patients revealed no limitations during catheterization and deployment of these devices. One patient had to be converted to coil embolization, which was feasible through the same vascular access. None of the patients had vascular complications postoperatively with minimal wrist discomfort.
引用
- Mouchtouris N, Al Saiegh F, Sweid A, et al. Transradial Access for Newly Food and Drug Administration-Approved Devices for Endovascular Treatment of Cerebral Aneurysms: A Technical Note. World Neurosurg. 2019. PMID: 31356971. doi:10.1016/j.wneu.2019.07.149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。